يعرض 2,001 - 2,020 نتائج من 5,116 نتيجة بحث عن '(( significant clinical decrease ) OR ( significant ((larger decrease) OR (largest decrease)) ))', وقت الاستعلام: 0.47s تنقيح النتائج
  1. 2001

    Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... حسب Gyeong Ho Baek (21382907)

    منشور في 2025
    "…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …"
  2. 2002

    Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... حسب Gyeong Ho Baek (21382907)

    منشور في 2025
    "…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …"
  3. 2003

    Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... حسب Gyeong Ho Baek (21382907)

    منشور في 2025
    "…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …"
  4. 2004

    Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... حسب Gyeong Ho Baek (21382907)

    منشور في 2025
    "…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …"
  5. 2005
  6. 2006
  7. 2007

    Schematic flowchart of the study. حسب Sivaprakasam T. Selvavinayagam (13825861)

    منشور في 2025
    "…Factors such as individuals’ age (p = 0.029), underlying comorbid conditions (30.3%; p = 0.035), and longer employment duration (28%; p = 0.034) were significantly associated with IGRA positivity. Further, IGRA positivity was significantly associated with decreased RDW standard deviation (RDW-SD). …"
  8. 2008

    Comorbidities among LTBI-positive individuals. حسب Sivaprakasam T. Selvavinayagam (13825861)

    منشور في 2025
    "…Factors such as individuals’ age (p = 0.029), underlying comorbid conditions (30.3%; p = 0.035), and longer employment duration (28%; p = 0.034) were significantly associated with IGRA positivity. Further, IGRA positivity was significantly associated with decreased RDW standard deviation (RDW-SD). …"
  9. 2009
  10. 2010

    Summary of correlations in previous studies. حسب Dan Kuang (136225)

    منشور في 2025
    "…During this period, the number of weekly new cases exhibited a similar trend, and the results indicated a significant correlation between the viral concentration and the number of weekly new cases (spearman’s r = 0.93, P < 0.001). …"
  11. 2011

    The characteristics of nine WWTPs. حسب Dan Kuang (136225)

    منشور في 2025
    "…During this period, the number of weekly new cases exhibited a similar trend, and the results indicated a significant correlation between the viral concentration and the number of weekly new cases (spearman’s r = 0.93, P < 0.001). …"
  12. 2012

    Variables name and variable measurement. حسب Jinyuan Li (5927267)

    منشور في 2025
    "…</p><p>Results</p><p>In the first period of DRG reform, total hospital costs decreased by 1.23% per month (95% CI, 0.88%-1.59%), patient cost-sharing decreased by 1.46% per month (95% CI, 1.09%-1.83%), patient sharing ratio decreased by 0.23% per month (95% CI, 0.06%-0.40%), and length of stay decreased by 0.56% per month (95% CI, 0.27%-0.84%). …"
  13. 2013
  14. 2014
  15. 2015
  16. 2016
  17. 2017
  18. 2018
  19. 2019
  20. 2020